Cytori Therapeutics IncFind Ratings Reports
CYTORI THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. CYTORI THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.78 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 40.01% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||1.5||2.83|
|Net Income ($mil)||-6.05||-6.4|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||9.46||20.04|
|Total Assets ($mil)||32.48||42.68|
|Total Debt ($mil)||14.52||17.16|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||60.2||32.67|
|Return on Assets||-73.58||-30.4|
|Return on Equity||-212.78||-69.32|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||33.33||20.49|
|Div / share||0.0||0.0|
|Book value / share||0.34||0.91|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||854581.0||855458.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.22 indicates a significant discount versus the S&P 500 average of 3.11 and a significant discount versus the industry average of 12.06. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|CYTX NM||Peers 39.29||CYTX NM||Peers 27.33|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CYTX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CYTX's P/CF is negative making the measure meaningless.
|CYTX NA||Peers 25.51||CYTX NA||Peers 0.49|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CYTX 1.22||Peers 12.06||CYTX 0.98||Peers 9.89|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CYTX is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CYTX is expected to significantly trail its peers on the basis of its earnings growth rate.
|CYTX 1.56||Peers 99.07||CYTX -24.58||Peers 241.27|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CYTX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CYTX significantly trails its peers on the basis of sales growth